Difficulties of managing a patient with acute myocardial infarction, severe anemia, and cirrhosis
https://doi.org/10.24884/1682-6655-2023-22-2-58-66
Abstract
It is now, known that liver diseases, including cirrhosis, are associated with a higher cardiovascular risk compared with the general population. The management of patients with cirrhosis and acute coronary syndrome is associated with the risk of various complications. The clinical case presented in the publication showed significant risks that have direct and indirect influence on the outcome and further prognosis of a patient with myocardial infarction and cirrhosis, namely: ischemic risks, hemorrhagic risks, surgical and somatic risks.
About the Authors
A. S. Kuznetsova
South-Ural State Medical University; Clinical Hospital «Russian Railways-Medicine»
Russian Federation
Russian Federation
Kuznetsova Alla S. – РhD, Assistant of the Department of Clinical Therapy
64, Vorovskogo str., Chelyabinsk, 454092
23, Dovatora str., Chelyabinsk, 454048
K. A. Kireev
South-Ural State Medical University; Clinical Hospital «Russian Railways-Medicine»
Russian Federation
Russian Federation
Kireev Konstantin A. – РhD, Associate Professor, Head of the Center of Endovascular Methods of Diagnosis and Treatment, Professor of the Department of Surgery
64, Vorovskogo str., Chelyabinsk, 454092
23, Dovatora str., Chelyabinsk, 454048
V. V. Genkel
South-Ural State Medical University; Clinical Hospital «Russian Railways-Medicine»
Russian Federation
Russian Federation
Genkel Vadim V. – PhD, Assistant of the Department of Propaedeutics of Internal Medicine
64, Vorovskogo str., Chelyabinsk, 454092
23, Dovatora str., Chelyabinsk, 454048
V. V. Fastakovsky
South-Ural State Medical University
Russian Federation
Russian Federation
Fastakovsky Vladimir V. – 2nd-year Resident at the Department of Surgery, Institute of Supplementary Professional Education
64, Vorovskogo str., Chelyabinsk, 454092
S. A. Rusanova
Clinical Hospital «Russian Railways-Medicine»
Russian Federation
Russian Federation
Rusanova Svetlana A. – Cardiologist
23, Dovatora str., Chelyabinsk, 454048
G. A. Treiger
South-Ural State Medical University
Russian Federation
Russian Federation
Treiger Georgiy A. – Assistant of the Department of Surgery, Institute of Additional Professional Education
23, Dovatora str., Chelyabinsk, 454048
References
1. Kalaitzakis E, Rosengren A, Skommevik T, Björnsson E. Coronary artery disease in patients with liver cirrhosis // Dig Dis Sci. 2010;55(2):467–475. Doi: 10.1007/s10620-009-0738-z.
2. Ahmed T, Grigorian AY, Messerli AW. Management of Acute Coronary Syndrome in Patients with Liver Cirrhosis // Am J Cardiovasc Drugs. 2022;22(1):55–67. Doi: 10.1007/s40256-021-00478-6.
3. Vanecek R. Atherosclerosis and cirrhosis of the liver // Bull World Health Organ. 1976;53(5–6):567–570.
4. Lin SY, Lin CL, Lin CC et al. Risk of acute coronary syndrome and peripheral arterial disease in chronic liver disease and cirrhosis: a nationwide population-based study // Atherosclerosis. 2018;270:154–159. Doi: 10.1016/j.atherosclerosis.2018.01.047.
5. Lisman T. Hemostatic Alterations in Liver Disease: A Review on Pathophysiology, Clinical Consequences, and Treatment // Digestive surg. 2007;24(4):250–258. Doi: 10. 1159/000103655.
6. Northup PG. Hypercoagulation in liver disease // Clinics in Liver Disease. 2009;13(1):109–116. Doi: 10.1016/j.cld.2008.09.003.
7. Тугушев А.С. Цирроз печени и тромбоз. Запорожский мед. журн. – 2010. – № 3. – С. 78–83.
8. Кашталап В.В., Завырылина И.Н., Барбараш О.Л. Эндоваскулярная реваскуляризация при остром коронарном синдроме с подъемом сегмента ST в России: проблемы и перспективы дальнейшего развития // Креатив. кардиол. – 2015. – № 3. – С. 5–15.
9. Оганов Р.Г., Симаненков В.И., Бакулин И.Г. и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения // Кардиоваск. тер. и профилактика. – 2019. – Т. 1, № 18. – С. 5–66.
10. Корой П.В., Витковская М.А., Раевская А.И. и др. Ишемическая болезнь сердца при циррозе печени: современные реалии // Лечащий врач. – 2020. – № 2. – С. 6–9.
11. Коморбидность больных циррозом печени: влияние на течение и исходы / Олевская Е.Р., Долгушина А.И., Тарасов А.Н., Хихлова А.О. // Эксперимент. и клин. гастроэнтерол. – 2018. – Т. 157, № 9. – С. 57–63.
12. Морозова В.Д., Глушаков И.А., Калюта Т.Ю. и др. Анемия при остром коронарном синдроме: прогностическое значение и лечение // Терапия. – 2021. – № 3. – С. 74–79.
13. Kuo L, Chao TF, Liu CJ et al. Liver cirrhosis in patients with atrial fbrillation: would oral anticoagulation have a net clinical beneft for stroke prevention? // J Am Heart Assoc. 2017;6(6):e005307. Doi: 10.1161/JAHA.116.005307.
14. Осадчук А.М., Осадчук М.М., Золотовская И.А. Тромботические осложнения у пациентов с циррозом печени: современное состояние проблемы // Терапия. – 2021. – Т. 7, № 49. – С. 112–117.
15. Valeriani E, Riva N, Di Nisio M, Ageno W. Splanchnic Vein Thrombosis: Current Perspectives // Vasc Health Risk Manag. 2019;(15):449–461. Doi: 10.2147/VHRM.S197732.
16. Yasuda H, Yamada M, Sawada S et al. Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting // Intern Med. 2009;48(19):1725–1730. Doi: 10.2169/internalmedicine.48.2031.
17. Russo MW, Pierson J, Narang T et al. Coronary artery stents and antiplatelet therapy in patients with cirrhosis // J Clin Gastroenterol. 2012;46(4):339–344. Doi: 10.1097/MCG. 0b013e3182371258
18. Azarbal B, Poommipanit P, Arbit B et al. Feasibility and safety of percutaneous coronary intervention in patients with end-stage liver disease referred for liver transplantation // Liver Transpl. 2011;17(7):809–813. Doi: 10.1002/lt.22301.
19. Urban P, Mehran R, Colleran R et al. Defning high bleeding risk in patients undergoing percutaneous coronary intervention. A consensus document from the academic research consortium for high bleeding risk // Circulation. 2019; 140(3):240–261. Doi: 10.1093/eurheartj/ehz372.
20. Qamar AA, Grace ND, Groszmann RJ, Garcia-Tsao G, Bosch J, Burroughs AK, Ripoll C, Maurer R, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Makuch R, Rendon G; Portal Hypertension Collaborative Group. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis // Clin Gastroenterol Hepatol. 2009;7(6):689–695. Doi: 10.1016/j.cgh.2009.02.021.
21. Ostojic Z, Ostojic A, Bulum J, Mrzljak A. Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease // World J Cardiol. 2021;13(11):599–607. Doi: 10. 4330/wjc.v13.i11.599.
22. Vetrovec G, Stravitz RT. Bleeding in Patients With Cirrhosis Undergoing Invasive Cardiovascular Procedures: Do We Overestimate Risk? // Circulation. 2020;141(16):1279–1281. Doi: 10.1161/CIRCULATIONAHA.120.043561.
23. Анализ эффективности различных способов гемостаза и профилактики кровотечения при портальной гипертензии / Олевская Е.Р., Тарасов А.Н., Долгушина А.И., Микуров А.А. // Эксперимент. и клин. гастроэнтерол. – 2016; – Т. 131, № 7. – С. 95–100.
24. McCarthy CP, Steg PG, Bhatt DL. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical condorum // Eur Heart J. 2017; 38(47):3488–3492. Doi: 10.1093/eurheartj/ehx531.
Review
For citations:
Kuznetsova A.S., Kireev K.A., Genkel V.V., Fastakovsky V.V., Rusanova S.A., Treiger G.A. Difficulties of managing a patient with acute myocardial infarction, severe anemia, and cirrhosis. Regional blood circulation and microcirculation. 2023;22(2):58-66. (In Russ.) https://doi.org/10.24884/1682-6655-2023-22-2-58-66
Views:
628
Email this article 
